If you have atopic dermatitis ... the FDA approved nemolizumab (Nemluvio) for people 12 and older with moderate-to-severe AD that hasn’t improved with prescription creams or ointments.

The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

The FDA had been due ... and caregivers.” Approval in atopic dermatitis could unlock additional sales momentum for Zoryve, which is available in a 0.3% cream for psoriasis and a 0.3% topical ...

Ruxolitinib cream is effective for atopic dermatitis and prurigo nodularis ... 1/2 inhibitor, was initially approved by the FDA as a treatment for AD in September 2021. 1 This was based on ...

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

This application seeks approval for the treatment of mild to moderate atopic dermatitis or AD in children aged 2 to 5 years. The US regulatory agency's decision on the sNDA for ZORYVE cream 0.05% ...

Therapy for atopic ... dermatitis. These medications also have anti-inflammatory affects, but do not contain steroids. The two medications offered are pimecrolimus and tacrolimus, and both are ...

In the past 5 to 10 years, there has been a significant increase in treatment options for people with eczema, also known as atopic dermatitis ... Administration (FDA) has approved four biologics ...